Memorial Sloan - Kettering Cancer Center

What Memorial Sloan - Kettering Cancer Center does

Memorial Sloan Kettering Cancer Center (MSK) is a private nonprofit cancer treatment and research institution founded in 1884 and headquartered at 1275 York Avenue in Manhattan, with 10,000+ employees and regional outpatient facilities across New York, New Jersey, Westchester, and Long Island. MSK serves adult and pediatric oncology patients through a vertically integrated model spanning direct patient care (surgery, radiation, chemotherapy, immunotherapy, clinical trials), basic and translational research across 100+ labs at the Sloan Kettering Institute, and a graduate school (Gerstner Sloan Kettering Graduate School of Biomedical Sciences). Revenue is generated through patient care billed via insurance, sponsored research and grants (e.g., $23M NCI telehealth grant, $12M+ from Break Through Cancer), technology licensing (MSK-IMPACT and MSK-ACCESS via SOPHiA GENETICS in 35 countries), and, as of 2026, MSK Ventures, a dedicated venture capital fund investing in early-stage therapeutics, diagnostics, and AI-enabled oncology platforms.

MSK's core technology portfolio includes proprietary genomic profiling assays (MSK-IMPACT for tumor tissue, MSK-ACCESS for liquid biopsy ctDNA), the ECHO optimization engine for automated radiation therapy planning, and an AI-enabled liquid biopsy using carbon nanotube nanosensors that achieved 98% accuracy in brain tumor classification (published in Nature Nanotechnology). The institution maintains a data flywheel anchored by 150,000+ sequenced tumor samples and pan-cancer data from 54,331 tumors across 48,179 patients published through cBioPortal. Go-to-market operates as a referral-based direct-care institution: the Physician Relations team and a dedicated clinician access line (833-315-2722) drive enterprise physician referrals, while approximately 5,000 patients annually travel over 150 miles for care, indicating national and international demand. MSK has aggressively built an AI/ML stack through partnerships with AWS (Amazon Bio Discovery for antibody design), OpenAI (GPT-5.2 for clinical documentation), Tempus AI (open-source digital pathology), BostonGene (multiomics for blood cancers), and Insilico Medicine (PandaOmics for gastroesophageal targets).

The institution's strategic posture in 2026 reflects both offensive investment and operating pressure: MSK launched MSK Ventures (Fund I targeting 2026), broke ground on the Kenneth C. Griffin Pavilion (a $400M, 27-story inpatient facility expected ~2030), and executed multiple technology and licensing deals, while simultaneously reporting a $62M operating loss tied to Epic EHR implementation costs and facing leadership transitions in radiation oncology and breast imaging.

Name

Memorial Sloan - Kettering Cancer Center

Legal name

Memorial Sloan Kettering Cancer Center

Website

https://mskcc.org

Company type

Private

Founded year

1884

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Memorial Sloan Kettering Cancer Center (MSK), founded in 1884 in New York, is a nonprofit cancer hospital and research institute treating adult and pediatric oncology patients, operating 10,000+ employees across Manhattan and regional facilities in NY/NJ. It combines patient care, basic and translational research across 100+ labs, technology licensing (MSK-IMPACT, MSK-ACCESS), and a 2026-launched venture capital fund.

Ownership category

akta.pro rank

Product category

Cancer Care and Oncology Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Surgical Oncology (HLAKAFAG)

Keywords

• Cancer treatment services
• Precision oncology diagnostics
• Clinical trial research
• Genomic profiling assays
• Radiation therapy planning

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others, Marketing or Sales

Revenue model

1. Patient Care Services: MSK generates revenue through direct patient care including cancer treatment, surgery, radiation therapy, immunotherapy, and other clinical services. The institution accepts most insurance plans and offers financial assistance programs.
2. Sponsored Research and Grants: MSK receives funding through research grants from organizations including the National Cancer Institute, Break Through Cancer, and private foundations, supporting clinical trials and translational research.
3. Technology Licensing and Royalties: MSK licenses its diagnostic technologies (MSK-IMPACT, MSK-ACCESS) and other intellectual property to commercial partners like SOPHiA GENETICS, generating licensing revenue.
4. MSK Ventures Investment Returns: MSK's venture capital fund (MSK Ventures) invests in companies affiliated with MSK science and intellectual property, targeting early-stage therapeutics, diagnostics, and AI-enabled oncology platforms to generate financial returns.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Memorial Sloan Kettering Cancer Center provides comprehensive cancer care across all cancer types for adult and pediatric patients, including diagnosis, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, clinical trials, and survivorship programs. The center also develops and licenses proprietary precision oncology diagnostics (MSK-IMPACT, MSK-ACCESS) and runs an extensive translational research program across the Sloan Kettering Institute with 9 programs and over 100 laboratories.

Product overview

Memorial Sloan Kettering Cancer Center (MSK) operates as a comprehensive cancer care and research institution offering a portfolio of precision oncology products and services. The core diagnostic portfolio includes MSK-IMPACT® (comprehensive genomic profiling of tumor samples) and MSK-ACCESS® (blood-based liquid biopsy ctDNA test), both available globally through a Sophia Genetics partnership in 35 countries. MSK has established a Precision Oncology Hub joint venture with Sophia Genetics combining 150,000+ sequenced tumor samples with the SOPHiA DDM™ AI platform. The institution offers AI-enabled products including a carbon nanotube nanosensor liquid biopsy for brain tumors (98% accuracy), the ECHO optimization engine for radiation therapy planning, and participates in the open-source digital pathology IMS Consortium with Tempus AI. MSK@Home telehealth services and the MATCHES Telehealth Research Center (backed by $23M NCI grant) extend care delivery. MSK Ventures, the institution's dedicated venture capital fund launching in 2026, will invest in early-stage therapeutics, diagnostics, and AI-enabled oncology platforms aligned with MSK science and IP. Research data from over 54,000 tumors is publicly shared through cBioPortal.

Differentiator

Problem solved

Functional benefit

Brands

• MSK-IMPACT: A targeted genomic profiling assay developed by MSK for comprehensive cancer mutation profiling.
• MSK-ACCESS
• MSK@Home
• MSK Ventures
• Sloan Kettering Institute
• Gerstner Sloan Kettering Graduate School of Biomedical Sciences
• MATCHES Telehealth Research Center
• ECHO Optimization Engine

Products and services

• MSK-IMPACT
• MSK-ACCESS
• Precision Oncology Hub (SOPHiA GENETICS & MSK)
• AI Nanosensor Liquid Biopsy for Brain Tumors
• ECHO Optimization Engine
• MSK Ventures
• MATCHES Telehealth Research Center
• MSK cBioPortal Pan-Cancer Data Platform
• Digital Pathology IMS Consortium
• Autogene Cevumeran mRNA Cancer Vaccine
• Comprehensive Cancer Patient Care Services
• Amazon Bio Discovery Antibody Design Platform

Quantifiable outcome

• People treated for cancer at MSK live better, longer based on Medicare patient data adjusted survival rate for all cancers combined compared to all NCI-Designated Comprehensive Cancer Centers.
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability17 records

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Seres TherapeuticscoreStrategic or Co-development Partner · 25 June 2026Investigator-sponsored trial at MSK evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis. SER-155 has received Breakthrough Therapy and Fast Track designations from the FDA and is also being developed for preventing bloodstream infections in stem cell transplant patients.
• Quest Diagnostics (Haystack Oncology)coreTechnology or Integration · 24 June 2026Clinical utility of Haystack MRD ctDNA test demonstrated in landmark study led by MSK and published in NEJM. The test identifies residual or recurring disease in solid tumor cancer patients, with ctDNA testing identifying clinical complete response at median of 1.4 months compared to over 6 months using imaging methods.
• BostonGenecoreStrategic or Co-development Partner · 8 June 2026Collaborative research at EHA2026 Congress demonstrating BostonGene's AI-driven multiomics platforms integrated with MSK clinical data for optimizing risk stratification and predicting treatment response in blood cancers including CAR-T therapy resistance.
• SOPHiA GENETICScoreStrategic or Co-development Partner · 4 June 2026MOU signed to establish a precision oncology hub in New York City combining MSK's clinical data and cancer diagnostics expertise with SOPHiA GENETICS' AI analytics platform (SOPHiA DDM™). The hub aims to build a global precision medicine hub for multimodal precision oncology, accelerating discoveries from research to clinical care and expanding access globally. Builds on previous successful license agreements involving MSK-IMPACT and MSK-ACCESS diagnostics already available in 35 countries.
• Greatly HealthcoreStrategic or Co-development Partner · 30 April 2026Virtual integrative oncology platform originally developed and validated at MSK, demonstrating 16% absolute improvement in overall survival at two years and 69% reduction in hospitalizations. Greatly Health raised $4M seed round to scale the platform.
• BioNTech and GenentechcoreStrategic or Co-development Partner · 21 April 2026Co-development of autogene cevumeran personalized mRNA neoantigen vaccine for pancreatic cancer. Phase 1 trial showed 7 of 8 vaccine responders remained alive 4-6 years post-treatment, with larger Phase 2 trial (IMCODE003) now recruiting.
• Amazon Web Services (AWS)coreTechnology or Integration · 14 April 2026Collaboration using Amazon Bio Discovery platform where MSK designed nearly 300,000 novel antibody molecules, narrowed to top 100,000 for testing by Twist Bioscience. The platform integrates biological foundation models with wet-lab testing partners to compress antibody design timelines from a year to weeks.
• Tempus AIcoreStrategic or Co-development Partner · 14 April 2026Launch of open-source digital pathology IMS Consortium with Yale New Haven Hospital and MSK as founding members. The consortium aims to develop a standardized, open digital pathology platform by open sourcing Tempus's existing system including slide viewer, case management, and AI modules.
• LumonuscoreStrategic or Co-development Partner · 8 April 2026Strategic collaboration to integrate MSK's ECHO optimization engine into Lumonus AI platform for radiation therapy treatment planning. The partnership aims to improve quality, consistency, and efficiency of automated radiation therapy planning through joint research and licensing.
• ARISciencecoreStrategic or Co-development Partner · 26 March 2026Collaboration with MSK Therapeutics Accelerator to advance novel precision small molecule therapeutic candidates targeting metastasis. ARIScience gains access to MSK's drug development resources and translational expertise, combining AI, quantum chemistry, and computer vision capabilities with MSK's clinical and scientific resources.
• Granny-O-LaminorOthers · 25 March 2026Premium granola brand launched with mission to donate 50% of profits to MSK, supporting cancer research and care through consumer purchases.
• Insilico MedicinecoreStrategic or Co-development Partner · 18 February 2026Collaboration using AI and multi-omic clinical datasets for discovering novel therapeutic targets for gastroesophageal cancers. Leverages Insilico's PandaOmics platform and MSK's extensive clinical data to accelerate drug discovery and personalize treatments.
• OpenAIcoreTechnology or Integration · 20 January 2026MSK is among major health systems deploying OpenAI for Healthcare, powered by GPT-5.2 models, for patient chart summarization, clinical documentation, and care coordination workflows.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 18 August 2022$23 million grant over five years awarded to establish MATCHES Telehealth Research Center for research into telehealth cancer care, evaluating MSK@Home supporting routine oncology care at patients' homes via telehealth.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

• Xx.com/sloan_kettering
• YouTubeyoutube.com/user/mskcc
• Facebookfacebook.com/sloankettering
• LinkedInlinkedin.com/company/5630
• Instagraminstagram.com/memorialsloankettering

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Memorial Sloan - Kettering Cancer Center